Plus Therapeutics (PSTV) EBIAT (2016 - 2025)
Plus Therapeutics (PSTV) has disclosed EBIAT for 15 consecutive years, with -$4.4 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 53.9% to -$4.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$20.6 million, a 59.86% decrease, with the full-year FY2024 number at -$13.0 million, up 2.37% from a year prior.
- EBIAT was -$4.4 million for Q3 2025 at Plus Therapeutics, down from $5.2 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $5.2 million in Q2 2025 to a low of -$17.4 million in Q1 2025.
- A 5-year average of -$4.0 million and a median of -$3.8 million in 2021 define the central range for EBIAT.
- Biggest YoY gain for EBIAT was 275.2% in 2025; the steepest drop was 433.61% in 2025.
- Plus Therapeutics' EBIAT stood at -$3.7 million in 2021, then tumbled by 53.17% to -$5.7 million in 2022, then soared by 32.66% to -$3.8 million in 2023, then dropped by 3.02% to -$3.9 million in 2024, then fell by 12.69% to -$4.4 million in 2025.
- Per Business Quant, the three most recent readings for PSTV's EBIAT are -$4.4 million (Q3 2025), $5.2 million (Q2 2025), and -$17.4 million (Q1 2025).